| Product Name | CD43 Monoclonal Antibody |
|---|---|
| Description | CD43 is mainly marked on T cells and expressed in normal T lymphocytes, myeloid cells, macrophages and plasma cells. Normal B cells or reactive B cells are CD43-. Expression of CD43 in various lymphatic hematopoietic tumors is complex. 90% T lymphocytic lymphoma are CD43+, 30% low grade B cell lymphoma are CD43+, 69% B cell acute lymphoblastic leukemia are CD43+, 97% T cell acute lymphoblastic leukemia are CD43+, 44% anaplastic large cell lymphoma are CD43+, all extramedullary myeloma / granulocytic sarcoma are CD43+, and part of myeloma CD43 are positive. It is usually detected combined with other T cell markers such as CD3 and CD45RO for diagnosis of T cell lymphoma.One of the major glycoproteins of thymocytes and T lymphocytes. Plays a role in the physicochemical properties of the T-cell surface and in lectin binding. Presents carbohydrate ligands to selectins. Has an extended rodlike structure that could protrude above the glycocalyx of the cell and allow multiple glycan chains to be accessible for binding. Is a counter-receptor for SN/Siglec-1 . During T-cell activation is actively removed from the T-cell-APC (antigen-presenting cell) contact site thus suggesting a negative regulatory role in adaptive immune response. |
| Synonyms | Leukosialin,Galactoglycoprotein,GALGP,Leukocyte sialoglycoprotein,Sialophorin,CD antigen CD43 |
| Host | Mouse |
| Clone | 2B1 |
| Immunogen | Full length protein from eukaryotic expression system. |
| Isotype | IgG |
| Specificity | This antibody detects endogenous levels of CD43 |
| Reactivity | Human |
| Applications | IHC |
| Form | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Uniprot | P16150 |
| Background | CD43 is mainly marked on T cells and expressed in normal T lymphocytes, myeloid cells, macrophages and plasma cells. Normal B cells or reactive B cells are CD43-. Expression of CD43 in various lymphatic hematopoietic tumors is complex. 90% T lymphocytic lymphoma are CD43+, 30% low grade B cell lymphoma are CD43+, 69% B cell acute lymphoblastic leukemia are CD43+, 97% T cell acute lymphoblastic leukemia are CD43+, 44% anaplastic large cell lymphoma are CD43+, all extramedullary myeloma / granulocytic sarcoma are CD43+, and part of myeloma CD43 are positive. It is usually detected combined with other T cell markers such as CD3 and CD45RO for diagnosis of T cell lymphoma.One of the major glycoproteins of thymocytes and T lymphocytes. Plays a role in the physicochemical properties of the T-cell surface and in lectin binding. Presents carbohydrate ligands to selectins. Has an extended rodlike structure that could protrude above the glycocalyx of the cell and allow multiple glycan chains to be accessible for binding. Is a counter-receptor for SN/Siglec-1 . During T-cell activation is actively removed from the T-cell-APC (antigen-presenting cell) contact site thus suggesting a negative regulatory role in adaptive immune response. |
| Supplier | Elabscience |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
